Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE 205: Lenvatinib +/- Everolimus in Advanced RCC
NCT01136733Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of lenvatinib in renal cell carcinoma (RCC), sponsored by Eisai Co., Ltd.. Started Aug 2010; status: completed.
02
Drugs
lenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01136733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01136733.